Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 144
Filter
Add more filters

Complementary Medicines
Country/Region as subject
Publication year range
1.
J Immunol Methods ; 510: 113358, 2022 11.
Article in English | MEDLINE | ID: mdl-36126779

ABSTRACT

Ferroptosis, a type of iron-dependent necrotic cell death, is specifically associated with increased lipid peroxidation. The dysfunction of the glutathione (GSH) production via the starvation of cysteine or the inhibition of phospholipid hydroperoxide glutathione peroxidase (GPX4) typically results in the accumulation of lipid peroxidation products and, consequently, the development of ferroptosis. We recently reported on the production of a rat monoclonal antibody, referred to as FerAb, against mouse-derived Hepa 1-6 cells that had been cultivated in cystine-deprived medium. Immunocytological analyses by means of fluorescence microscopy revealed that FerAb binds to fixed ferroptotic cells regardless of the species from which they were obtained, but not to apoptotic cells. We report herein on an in-depth characterization of the reactivity of FerAb with respect to unfixed cells by means of flow cytometry. The binding of FerAb to the cells was stimulated by incubating the cells in cystine deprived culture medium or treatment with RSL3, a GPX4 inhibitor, while treatment with staurosporine, an apoptosis inducer, had no effect on its binding to the cells. Supplementation with ferrostatin-1, a ferroptosis inhibitor, effectively suppressed the binding of FerAb to cells that had been cultivated in cystine-deprived medium or treated with RSL3, further confirming the specific binding of FerAb to ferroptotic cells. Thus, FerAb combined with a flow cytometry can be used to distinguish ferroptotic cells from living cells or apoptotic cells without the need for fixation. Applications of this combined technique will enable the quantitative evaluation of ferroptotic cells under a variety of patho-physiological conditions and will contribute to our understanding of the roles of ferroptosis in the body as well as cultured cells.


Subject(s)
Ferroptosis , Animals , Antibodies, Monoclonal/pharmacology , Cell Death , Cysteine , Cystine , Flow Cytometry , Glutathione/metabolism , Iron , Mice , Phospholipid Hydroperoxide Glutathione Peroxidase , Rats , Staurosporine/pharmacology
2.
Brief Bioinform ; 23(1)2022 01 17.
Article in English | MEDLINE | ID: mdl-34962256

ABSTRACT

The pharmacological arsenal against the COVID-19 pandemic is largely based on generic anti-inflammatory strategies or poorly scalable solutions. Moreover, as the ongoing vaccination campaign is rolling slower than wished, affordable and effective therapeutics are needed. To this end, there is increasing attention toward computational methods for drug repositioning and de novo drug design. Here, multiple data-driven computational approaches are systematically integrated to perform a virtual screening and prioritize candidate drugs for the treatment of COVID-19. From the list of prioritized drugs, a subset of representative candidates to test in human cells is selected. Two compounds, 7-hydroxystaurosporine and bafetinib, show synergistic antiviral effects in vitro and strongly inhibit viral-induced syncytia formation. Moreover, since existing drug repositioning methods provide limited usable information for de novo drug design, the relevant chemical substructures of the identified drugs are extracted to provide a chemical vocabulary that may help to design new effective drugs.


Subject(s)
Antiviral Agents/pharmacology , COVID-19 Drug Treatment , COVID-19 , Giant Cells , Pyrimidines/pharmacology , SARS-CoV-2/metabolism , Staurosporine/analogs & derivatives , A549 Cells , COVID-19/metabolism , Computational Biology , Drug Evaluation, Preclinical , Drug Repositioning , Giant Cells/metabolism , Giant Cells/virology , Humans , Staurosporine/pharmacology
3.
Int J Mol Sci ; 22(21)2021 Nov 04.
Article in English | MEDLINE | ID: mdl-34769389

ABSTRACT

BACKGROUND: Staurosporine-dependent single and collective cell migration patterns of breast carcinoma cells MDA-MB-231, MCF-7, and SK-BR-3 were analysed to characterise the presence of drug-dependent migration promoting and inhibiting yin-yang effects. METHODS: Migration patterns of various breast cancer cells after staurosporine treatment were investigated using Western blot, cell toxicity assays, single and collective cell migration assays, and video time-lapse. Statistical analyses were performed with Kruskal-Wallis and Fligner-Killeen tests. RESULTS: Application of staurosporine induced the migration of single MCF-7 cells but inhibited collective cell migration. With the exception of low-density SK-BR-3 cells, staurosporine induced the generation of immobile flattened giant cells. Video time-lapse analysis revealed that within the borderline of cell collectives, staurosporine reduced the velocity of individual MDA-MB-231 and SK-BR-3, but not of MCF-7 cells. In individual MCF-7 cells, mainly the directionality of migration became disturbed, which led to an increased migration rate parallel to the borderline, and hereby to an inhibition of the migration of the cell collective as a total. Moreover, the application of staurosporine led to a transient activation of ERK1/2 in all cell lines. CONCLUSION: Dependent on the context (single versus collective cells), a drug may induce opposite effects in the same cell line.


Subject(s)
Breast Neoplasms/drug therapy , Cell Movement , Enzyme Inhibitors/pharmacology , Staurosporine/pharmacology , Yin-Yang , Apoptosis , Breast Neoplasms/pathology , Cell Proliferation , Female , Humans , Signal Transduction , Tumor Cells, Cultured
4.
Minerva Med ; 111(5): 427-442, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32955823

ABSTRACT

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene arise in 25-30% of all acute myeloid leukemia (AML) patients. These mutations lead to constitutive activation of the protein product and are divided in two broad types: internal tandem duplication (ITD) of the juxtamembrane domain (25% of cases) and point mutations in the tyrosine kinase domain (TKD). Patients with FLT3 ITD mutations have a high relapse risk and inferior cure rates, whereas the role of FLT3 TKD mutations still remains to be clarified. Additionally, growing research indicates that FLT3 status evolves through a disease continuum (clonal evolution), where AML cases can acquire FLT3 mutations at relapse - not present in the moment of diagnosis. Several FLT3 inhibitors have been tested in patients with FLT3-mutated AML. These drugs exhibit different kinase inhibitory profiles, pharmacokinetics and adverse events. First-generation multi-kinase inhibitors (sorafenib, midostaurin, lestaurtinib) are characterized by a broad-spectrum of drug targets, whereas second-generation inhibitors (quizartinib, crenolanib, gilteritinib) show more potent and specific FLT3 inhibition, and are thereby accompanied by less toxic effects. Notwithstanding, all FLT3 inhibitors face primary and acquired mechanisms of resistance, and therefore the combinations with other drugs (standard chemotherapy, hypomethylating agents, checkpoint inhibitors) and its application in different clinical settings (upfront therapy, maintenance, relapsed or refractory disease) are under study in a myriad of clinical trials. This review focuses on the role of FLT3 mutations in AML, pharmacological features of FLT3 inhibitors, known mechanisms of drug resistance and accumulated evidence for the use of FLT3 inhibitors in different clinical settings.


Subject(s)
Antineoplastic Agents/pharmacology , Leukemia, Myeloid, Acute/drug therapy , Protein Kinase Inhibitors/pharmacology , Sorafenib/pharmacology , fms-Like Tyrosine Kinase 3/antagonists & inhibitors , fms-Like Tyrosine Kinase 3/genetics , Aniline Compounds/pharmacology , Benzimidazoles/pharmacology , Benzothiazoles/pharmacology , Carbazoles/pharmacology , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Forecasting , Furans , Hematopoietic Stem Cell Transplantation , Humans , Imidazoles/pharmacology , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/therapy , Maintenance Chemotherapy/methods , Mutation , Phenylurea Compounds/pharmacology , Piperidines/pharmacology , Point Mutation , Pyrazines/pharmacology , Pyridazines/pharmacology , Recurrence , Staurosporine/analogs & derivatives , Staurosporine/pharmacology
5.
J Biosci Bioeng ; 130(1): 106-113, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32253091

ABSTRACT

Monoclonal antibodies (mAbs) are active pharmaceutical ingredients in antibody drugs, produced mainly using recombinant Chinese hamster ovary (CHO) cells. The regulation of recombinant CHO cell proliferation can improve the productivity of heterologous proteins. Chemical compound approaches for cell cycle regulation have the advantages of simplicity and ease of use in industrial processes. However, CHO cells have genetic and phenotypic diversity, and the effects of such compounds might depend on cell line and culture conditions. Increasing the variety of cell cycle inhibitors is a promising strategy to overcome the dependency. Marine microorganisms are a vast and largely undeveloped source of secondary metabolites with physiological activity. In this study, we focused on secondary metabolites of marine microorganisms and evaluated their effectiveness as cell cycle inhibitory compounds. Of 720 extracts from microorganisms (400 actinomycetes and 320 filamentous fungi) collected from the Okinawan Sea, we identified nine extracts that decreased the specific growth rate and increased the specific production rate without reducing cell viability. After fractionating the extracts, the components of active fractions were estimated using time-of-flight mass spectrometry analysis. Then, four compounds, including staurosporine and undecylprodigiosin were deduced to be active compounds. These compounds have been reported to exert a cell cycle inhibitory effect on mammalian cells. These compounds might serve as additives to improve mAb production in CHO cells. This study indicates that secondary metabolites of marine microorganisms are a useful source for new cell cycle inhibitory compounds that can increase mAb production in CHO cells.


Subject(s)
Actinobacteria/chemistry , Cell Cycle/drug effects , Fungi/chemistry , Growth Inhibitors/pharmacology , Seawater/microbiology , Actinobacteria/genetics , Actinobacteria/isolation & purification , Actinobacteria/metabolism , Animals , CHO Cells , Cell Division/drug effects , Cell Survival/drug effects , Cricetinae , Cricetulus , Drug Evaluation, Preclinical , Fungi/genetics , Fungi/isolation & purification , Fungi/metabolism , Growth Inhibitors/metabolism , Prodigiosin/analogs & derivatives , Prodigiosin/metabolism , Prodigiosin/pharmacology , Staurosporine/metabolism , Staurosporine/pharmacology
6.
Anal Chem ; 92(1): 1363-1371, 2020 01 07.
Article in English | MEDLINE | ID: mdl-31794197

ABSTRACT

High-throughput drug discovery is highly dependent on the targets available to accelerate the process of candidates screening. Traditional chemical proteomics approaches for the screening of drug targets usually require the immobilization/modification of the drug molecules to pull down the interacting proteins. Recently, energetics-based proteomics methods provide an alternative way to study drug-protein interaction by using complex cell lysate directly without any modification of the drugs. In this study, we developed a novel energetics-based proteomics strategy, the solvent-induced protein precipitation (SIP) approach, to profile the interaction of drugs with their target proteins by using quantitative proteomics. The method is easy to use for any laboratory with the common chemical reagents of acetone, ethanol, and acetic acid. The SIP approach was able to identify the well-known protein targets of methotrexate, SNS-032, and a pan-kinase inhibitor of staurosporine in cell lysate. We further applied this approach to discover the off-targets of geldanamycin. Three known protein targets of the HSP90 family were successfully identified, and several potential off-targets including NADH dehydrogenase subunits NDUFV1 and NDUFAB1 were identified for the first time, and the NDUFV1 was validated by using Western blotting. In addition, this approach was capable of evaluating the affinity of the drug-target interaction. The data collectively proved that our approach provides a powerful platform for drug target discovery.


Subject(s)
HSP90 Heat-Shock Proteins/antagonists & inhibitors , Methotrexate/pharmacology , NADH Dehydrogenase/antagonists & inhibitors , Oxazoles/pharmacology , Proteomics , Staurosporine/pharmacology , Thiazoles/pharmacology , Acetic Acid/chemistry , Acetone/chemistry , Cells, Cultured , Drug Discovery , Drug Evaluation, Preclinical , Ethanol/chemistry , HEK293 Cells , HSP90 Heat-Shock Proteins/chemistry , HeLa Cells , High-Throughput Screening Assays , Humans , Methotrexate/chemistry , NADH Dehydrogenase/chemistry , NADH Dehydrogenase/metabolism , Oxazoles/chemistry , Solvents/chemistry , Staurosporine/chemistry , Thiazoles/chemistry
7.
Blood ; 134(9): 741-745, 2019 08 29.
Article in English | MEDLINE | ID: mdl-31243041

ABSTRACT

The natural history of FLT3-mutated AML is changing after the approval of midostaurin for frontline therapy and gilteritinib for relapsed or refractory patients. Recently reported, positive randomized trials of the drugs gilteritinib, quizartinib, and sorafenib predict even wider use of FLT3 inhibitors going forward. FLT3 inhibitors now emerge as an important, if not indispensable, part of therapy for a large subset of high-risk patients.


Subject(s)
Antineoplastic Agents/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Protein Kinase Inhibitors/therapeutic use , fms-Like Tyrosine Kinase 3/antagonists & inhibitors , Aniline Compounds/pharmacology , Aniline Compounds/therapeutic use , Animals , Antineoplastic Agents/pharmacology , Benzothiazoles/pharmacology , Benzothiazoles/therapeutic use , Clinical Trials as Topic , Humans , Phenylurea Compounds/pharmacology , Phenylurea Compounds/therapeutic use , Protein Kinase Inhibitors/pharmacology , Pyrazines/pharmacology , Pyrazines/therapeutic use , Sorafenib/pharmacology , Sorafenib/therapeutic use , Staurosporine/analogs & derivatives , Staurosporine/pharmacology , Staurosporine/therapeutic use
8.
Molecules ; 23(12)2018 Nov 29.
Article in English | MEDLINE | ID: mdl-30501110

ABSTRACT

Protein kinases are deeply involved in immune-related diseases and various cancers. They are a potential target for structure-based drug discovery, since the general structure and characteristics of kinase domains are relatively well-known. However, the ATP binding sites in protein kinases, which serve as target sites, are highly conserved, and thus it is difficult to develop selective kinase inhibitors. To resolve this problem, we performed molecular dynamics simulations on 26 kinases in the aqueous solution, and analyzed topological water networks (TWNs) in their ATP binding sites. Repositioning of a known kinase inhibitor in the ATP binding sites of kinases that exhibited a TWN similar to interleukin-1 receptor-associated kinase 4 (IRAK4) allowed us to identify a hit molecule. Another hit molecule was obtained from a commercial chemical library using pharmacophore-based virtual screening and molecular docking approaches. Pharmacophoric features of the hit molecules were hybridized to design a novel compound that inhibited IRAK4 at low nanomolar levels in the in vitro assay.


Subject(s)
Drug Design , Interleukin-1 Receptor-Associated Kinases/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Water/chemistry , Binding Sites , Drug Evaluation, Preclinical , Drug Repositioning , Molecular Docking Simulation , Protein Kinase Inhibitors/chemistry , Staurosporine/chemistry , Staurosporine/pharmacology
9.
Adv Exp Med Biol ; 1074: 649-653, 2018.
Article in English | MEDLINE | ID: mdl-29721999

ABSTRACT

Talaumidin, a tetrahydrofuran neolignan isolated from the root of Aristolochia arcuata, was an interesting small molecule with neurotrophic activity in the cultured neuron. Talaumidin can promote neurite outgrowth from neurons. However, the mechanism by which talaumidin exerts its neurotrophic actions on retinal neurons has not been elucidated to date. In this study, we describe that talaumidin has neurotrophic properties such as neurite outgrowth in neuroretinal cell line, RGC-5. Talaumidin promotes staurosporine-induced neurite outgrowth in RGC-5 cells. The neurite outgrowth effect of talaumidin was inhibited by phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, but not by Erk inhibitor, PD98059. These data suggest that talaumidin promotes neurite outgrowth through PI3K/Akt pathway and that the potential of talaumidin serves as a promising lead compound for the treatment of retinal degenerative disorders.


Subject(s)
Furans/pharmacology , Neuronal Outgrowth/drug effects , Neuroprotective Agents/pharmacology , Phosphatidylinositol 3-Kinases/physiology , Plant Extracts/pharmacology , Proto-Oncogene Proteins c-akt/physiology , Retinal Ganglion Cells/drug effects , Signal Transduction/drug effects , Animals , Cell Differentiation/drug effects , Cell Line , Chromones/pharmacology , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Mice , Morpholines/pharmacology , Phosphoinositide-3 Kinase Inhibitors , Phytotherapy , Protein Kinase Inhibitors/pharmacology , Retinal Degeneration/drug therapy , Retinal Ganglion Cells/ultrastructure , Staurosporine/pharmacology
11.
Mol Cancer Ther ; 16(1): 88-101, 2017 01.
Article in English | MEDLINE | ID: mdl-28062706

ABSTRACT

Improvements in survival for Ewing sarcoma pediatric and adolescent patients have been modest over the past 20 years. Combinations of anticancer agents endure as an option to overcome resistance to single treatments caused by compensatory pathways. Moreover, combinations are thought to lessen any associated adverse side effects through reduced dosing, which is particularly important in childhood tumors. Using a parallel phenotypic combinatorial screening approach of cells derived from three pediatric tumor types, we identified Ewing sarcoma-specific interactions of a diverse set of targeted agents including approved drugs. We were able to retrieve highly synergistic drug combinations specific for Ewing sarcoma and identified signaling processes important for Ewing sarcoma cell proliferation determined by EWS-FLI1 We generated a molecular target profile of PKC412, a multikinase inhibitor with strong synergistic propensity in Ewing sarcoma, revealing its targets in critical Ewing sarcoma signaling routes. Using a multilevel experimental approach including quantitative phosphoproteomics, we analyzed the molecular rationale behind the disease-specific synergistic effect of simultaneous application of PKC412 and IGF1R inhibitors. The mechanism of the drug synergy between these inhibitors is different from the sum of the mechanisms of the single agents. The combination effectively inhibited pathway crosstalk and averted feedback loop repression, in EWS-FLI1-dependent manner. Mol Cancer Ther; 16(1); 88-101. ©2016 AACR.


Subject(s)
Antineoplastic Agents/pharmacology , Drug Discovery , Drug Screening Assays, Antitumor , Molecular Targeted Therapy , Animals , Antigens, CD , Cell Line, Tumor , Computational Biology/methods , Disease Models, Animal , Drug Evaluation, Preclinical , Drug Interactions , Humans , Oncogene Proteins, Fusion/antagonists & inhibitors , Phosphorylation , Protein Kinase Inhibitors/pharmacology , Proteomics/methods , Proto-Oncogene Protein c-fli-1/antagonists & inhibitors , RNA-Binding Protein EWS/antagonists & inhibitors , Receptor, IGF Type 1 , Receptor, Insulin/antagonists & inhibitors , Receptors, Somatomedin/antagonists & inhibitors , Sarcoma, Ewing/drug therapy , Sarcoma, Ewing/genetics , Sarcoma, Ewing/metabolism , Sarcoma, Ewing/pathology , Signal Transduction/drug effects , Staurosporine/analogs & derivatives , Staurosporine/pharmacology , Xenograft Model Antitumor Assays
12.
ACS Chem Neurosci ; 7(7): 912-23, 2016 07 20.
Article in English | MEDLINE | ID: mdl-27213824

ABSTRACT

Alzheimer's disease (AD) is the most common brain disorder worldwide. Aberrant tau hyperphosphorylation and accumulation play critical roles in the formation of neurofibrillary tangles highly associated with neuronal dysfunction and cognitive impairment in AD pathogenesis. Glycogen synthase kinase-3ß (GSK3ß) is a key kinase responsible for tau hyperphosphorylation. Selective inhibition of GSK3ß is a promising strategy in AD therapy. Corn silks (CS, Zea mays L.) have been traditionally used as a medicinal herb and recently noted for their potentially cognitive benefits. However, the neuroprotective components of CS and their molecular mechanism have received little attention to date. As part of our effort screening phytochemicals against a broad panel of kinases targeting AD tauopathy, we found inhibition of GSK3ß by CS extracts. Subsequent bioassay-guided fractionation led to the isolation and identification of two 6-C-glycosylflavones, isoorientin (1) and 3'-methoxymaysin (2), with selective inhibition against GSK3ß in vitro. Enzyme kinetics and molecular docking studies demonstrated that 1 specifically inhibited GSK3ß via an ATP noncompetitive mechanism, acting as a substrate competitive inhibitor of GSK3ß. Further in vitro cellular studies demonstrated that 1 effectively attenuated tau phosphorylation mediated by GSK3ß and was neuroprotective against ß-amyloid-induced tau hyperphosphorylation and neurotoxicity in SH-SY5Y cells. The C-glycosylflavones represent new lead candidates with a novel mechanism of action for the development of AD phytopharmaceuticals.


Subject(s)
Amyloid beta-Peptides/pharmacology , Enzyme Inhibitors/pharmacology , Flavonoids/chemistry , Flavonoids/pharmacology , Glycogen Synthase Kinase 3/metabolism , Peptide Fragments/pharmacology , tau Proteins/metabolism , Adenosine Triphosphate/pharmacology , Cell Line, Tumor , Cell Survival/drug effects , Dose-Response Relationship, Drug , Enzyme Inhibitors/chemistry , Humans , Isoflavones/chemistry , Isoflavones/pharmacology , Luteolin/chemistry , Luteolin/pharmacology , Models, Chemical , Neuroblastoma/pathology , Phosphorylation/drug effects , Signal Transduction/drug effects , Staurosporine/pharmacology , tau Proteins/drug effects
13.
J Agric Food Chem ; 64(7): 1528-39, 2016 Feb 24.
Article in English | MEDLINE | ID: mdl-26832452

ABSTRACT

Increased apoptosis of retinal ganglion cells (RGCs) contributes to the gradual loss of retinal neurons at the early phase of diabetic retinopathy (DR). There is an urgent need to search for drugs with neuroprotective effects against apoptosis of RGCs for the early treatment of DR. This study aimed to investigate the neuroprotective effects of saponins extracted from Panax notoginseng, a traditional Chinese medicine, on apoptosis of RGCs stimulated by palmitate, a metabolic factor for the development of diabetes and its complications, and to explore the potential molecular mechanism. We showed that crude saponins of P. notoginseng (CSPN) inhibited the increased apoptosis and loss of postsynaptic protein PSD-95 by palmitate in staurosporine-differentiated RGC-5 cells. Moreover, CSPN suppressed palmitate-induced reactive oxygen species generation and endoplasmic reticulum stress-associated eIF2α/ATF4/CHOP and caspase 12 pathways. Thus, our findings address the potential therapeutic significance of CSPN for the early stage of DR.


Subject(s)
Drugs, Chinese Herbal/pharmacology , Endoplasmic Reticulum Stress/drug effects , Neuroprotective Agents/pharmacology , Palmitates/adverse effects , Panax notoginseng/chemistry , Retinal Ganglion Cells/cytology , Retinal Ganglion Cells/drug effects , Saponins/pharmacology , Apoptosis/drug effects , Cell Differentiation/drug effects , Humans , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Oxidative Stress/drug effects , SAP90-PSD95 Associated Proteins , Staurosporine/pharmacology
14.
Br J Pharmacol ; 173(1): 177-90, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26454020

ABSTRACT

BACKGROUND AND PURPOSE: Small conductance calcium-activated potassium (KCa 2.x) channels have a widely accepted canonical function in regulating cellular excitability. In this study, we address a potential non-canonical function of KCa 2.x channels in breast cancer cell survival, using in vitro models. EXPERIMENTAL APPROACH: The expression of all KCa 2.x channel isoforms was initially probed using RT-PCR, Western blotting and microarray analysis in five widely studied breast cancer cell lines. In order to assess the effect of pharmacological blockade and siRNA-mediated knockdown of KCa 2.x channels on these cell lines, we utilized MTS proliferation assays and also followed the corresponding expression of apoptotic markers. KEY RESULTS: All of the breast cancer cell lines, regardless of their lineage or endocrine responsiveness, were highly sensitive to KCa 2.x channel blockade. UCL1684 caused cytotoxicity, with LD50 values in the low nanomolar range, in all cell lines. The role of KCa 2.x channels was confirmed using pharmacological inhibition and siRNA-mediated knockdown. This reduced cell viability and also reduced expression of Bcl-2 but increased expression of active caspase-7 and caspase-9. Complementary to these results, a variety of cell lines can be protected from apoptosis induced by staurosporine using the KCa 2.x channel activator CyPPA. CONCLUSIONS AND IMPLICATIONS: In addition to a well-established role for KCa 2.x channels in migration, blockade of these channels was potently cytotoxic in breast cancer cell lines, pointing to modulation of KCa 2.x channels as a potential therapeutic approach to breast cancer.


Subject(s)
Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Gene Knockdown Techniques , Small-Conductance Calcium-Activated Potassium Channels/deficiency , Alkanes/toxicity , Apoptosis/drug effects , Apoptosis Regulatory Proteins/biosynthesis , Breast Neoplasms/genetics , Cell Line, Tumor , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Humans , Lethal Dose 50 , Protein Isoforms/biosynthesis , Protein Isoforms/deficiency , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Quinolinium Compounds/toxicity , RNA, Small Interfering/pharmacology , Small-Conductance Calcium-Activated Potassium Channels/biosynthesis , Small-Conductance Calcium-Activated Potassium Channels/genetics , Small-Conductance Calcium-Activated Potassium Channels/metabolism , Staurosporine/antagonists & inhibitors , Staurosporine/pharmacology
15.
Clin Exp Immunol ; 179(1): 75-84, 2015 Jan.
Article in English | MEDLINE | ID: mdl-24995908

ABSTRACT

Apoptosis of polymorphonuclear neutrophils (PMN) and subsequent 'silent' removal represents an important check-point for the resolution of inflammation. Failure in PMN clearance resulting in secondary necrosis-driven tissue damage has been implicated in conditions of chronic inflammation and autoimmunity. Apoptotic PMN undergo profound biophysical changes that warrant their efficient recognition and uptake by phagocytes before fading to secondary necrosis. In this study, we demonstrate that staurosporine (STS), a non-selective but potent inhibitor of cyclin-dependent kinase and protein kinase C, exerts a drastic impact on PMN apoptosis. PMN treated with STS underwent an unconventional form of cell death characterized by a delayed exposure of aminophospholipids, including phosphatidylserine (PS) and phosphatidylethanolamine and an increased exposure of neo-glycans. STS caused an impaired cellular fragmentation and accelerated DNA fragmentation. Phagocytosis of STS-treated PMN lacking PS on their surfaces was decreased significantly, which highlights the importance of PS for the clearance of apoptotic PMN. Specific opsonization with immune complexes completely restored phagocytosis of STS-treated PMN, demonstrating the efficiency of back-up clearance pathways in the absence of PS exposure.


Subject(s)
Apoptosis/immunology , Neutrophils/immunology , Antigen-Antibody Complex/immunology , Antigens, Surface/metabolism , Apoptosis/drug effects , Cells, Cultured , DNA Fragmentation/drug effects , Humans , Macrophages/drug effects , Macrophages/immunology , Macrophages/metabolism , Neutrophils/drug effects , Neutrophils/metabolism , Phagocytosis/drug effects , Phagocytosis/immunology , Phenotype , Phosphatidylserines/pharmacology , Staurosporine/pharmacology
16.
Antonie Van Leeuwenhoek ; 106(3): 515-25, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25035061

ABSTRACT

Chinese medicinal plants and their surrounding rhizospheric soil serve as promising sources of actinobacteria. A total of 180 actinobacteria strains were isolated from the rhizosphere soil, leaves, stems, and roots of nine selected plants and have been identified as potential biocontrol agents against Fusarium oxysporum f. sp. cucumerinum. An endophytic strain CNS-42 isolated from Alisma orientale showed the largest zone of inhibition demonstrating a potent effect against F. oxysporum f. sp. cucumerinum and a broad antimicrobial activity against bacteria, yeasts, and other pathogenic fungi. The in vivo biocontrol assays showed that the disease severity index was significantly reduced (P < 0.05), and plant shoot fresh weight and height increased greatly (P < 0.05) in plantlets treated with strain CNS-42 compared to the negative control. This isolate was identified as Streptomyces sp. based on cultural, physiological, morphological characteristics, and 16S rRNA gene analysis. Further bioassay-guided isolation and purification revealed that staurosporine was responsible for its antifungal and plant growth promoting activities and the latter property of staurosporine is reported for the first time. The in vivo assay was further performed and indicated that staurosporine showed good growth promoting effect on the plant shoot biomass of cucumber. This is the first critical evidence identifying CNS-42 as a biocontrol agent for the soil borne pathogen, F. oxysporum f. sp. cucumerinum.


Subject(s)
Antibiosis , Antifungal Agents/pharmacology , Plant Growth Regulators/pharmacology , Staurosporine/pharmacology , Streptomyces/physiology , Antifungal Agents/isolation & purification , Cucumis sativus/microbiology , Cucumis sativus/physiology , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , DNA, Ribosomal/chemistry , DNA, Ribosomal/genetics , Fusarium/drug effects , Fusarium/growth & development , Microscopy, Electron, Scanning , Molecular Sequence Data , Pest Control, Biological/methods , Plant Development , Plant Growth Regulators/isolation & purification , Plant Leaves/microbiology , Plant Roots/microbiology , Plant Stems/microbiology , RNA, Ribosomal, 16S/genetics , Sequence Analysis, DNA , Soil Microbiology , Staurosporine/isolation & purification , Streptomyces/chemistry , Streptomyces/classification , Streptomyces/isolation & purification
17.
Bratisl Lek Listy ; 115(4): 203-8, 2014.
Article in English | MEDLINE | ID: mdl-24797594

ABSTRACT

OBJECTIVES: In previous studies, we showed that staurosporine uses intracellular calcium ions to affect cell death in PC12 cells. The bulk release of intracellular excessive Ca(2+) from intracellular sources into cytosol contributes to neuronal apoptotic events, which in turn results in neuronal cell death. However, the mechanisms of Ca(2+)-induced neuronal cell death or neurite elongation is still unclear. Therefore, we investigated the relation between phosphoinositid signal pathway, intracellular calcium, and reactive oxygen species on one hand, with staurosporine-induced neurite outgrowth in PC12 cells on the other. RESULTS: The inhibition of phospholipase C or IP3 receptor antagonist or phosphoinositid signal transduction antagonist produced cell death and suppressed neurite outgrowth by staurosporine in PC12 cells. The inhibition of these enzymes and pathway results in an increase in intracellular Ca(2+) although subsequent hydroxyl radical (•OH) production began after inhibitors exposure. •OH production was significantly attenuated in inhibitor supplemented medium treatment, and it was dependent on the intracellular Ca(2+) concentration. These data indicate that staurosporine activates phosphoinositid signal pathway while endoplasmic Ca(2+), and subsequent •OH production are critical events in staurosporine-induced neurite outgrowth in PC12 cells. CONCLUSION: We conclude that the fact that staurosporine mobilizes Ca2+, probably via activating the subcellular compartment, is responsible for staurosporine-induced (Ca2+]i increase during neurite outgrowth in PC12 cells (Fig. 7, Ref. 30).


Subject(s)
Neurites/drug effects , Phospholipase C gamma/physiology , Signal Transduction/physiology , Staurosporine/pharmacology , Animals , Apoptosis/drug effects , Apoptosis/physiology , Calcium/metabolism , Inositol 1,4,5-Trisphosphate Receptors/antagonists & inhibitors , Neurites/physiology , PC12 Cells , Rats , Reactive Oxygen Species/metabolism
18.
J Neurochem ; 127(1): 57-65, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23815307

ABSTRACT

We reconstituted D2 like dopamine receptor (D2R) and the delta opioid receptor (DOR) coupling to G-protein gated inwardly rectifying potassium channels (K(ir)3) and directly compared the effects of co-expression of G-protein coupled receptor kinase (GRK) and arrestin on agonist-dependent desensitization of the receptor response. We found, as described previously, that co-expression of a GRK and an arrestin synergistically increased the rate of agonist-dependent desensitization of DOR. In contrast, only arrestin expression was required to produce desensitization of D2R responses. Furthermore, arrestin-dependent GRK-independent desensitization of D2R-K(ir)3 coupling could be transferred to DOR by substituting the third cytoplasmic loop of DOR with that of D2R. The arrestin-dependent GRK-independent desensitization of D2R desensitization was inhibited by staurosporine treatment, and blocked by alanine substitution of putative protein kinase C phosphorylation sites in the third cytoplasmic loop of D2R. Finally, the D2R construct in which putative protein kinase C phosphorylation sites were mutated did not undergo significant agonist-dependent desensitization even after GRK co-expression, suggesting that GRK phosphorylation of D2R does not play an important role in uncoupling of the receptor.


Subject(s)
Arrestin/physiology , G-Protein-Coupled Receptor Kinases/metabolism , Receptors, Dopamine D2/metabolism , Animals , Arrestins/physiology , Cloning, Molecular , Cytoplasm/metabolism , DNA, Complementary/biosynthesis , DNA, Complementary/genetics , Electrophysiological Phenomena , Enzyme Inhibitors/pharmacology , Female , Humans , Oocytes/metabolism , RNA, Complementary/biosynthesis , RNA, Complementary/genetics , Staurosporine/pharmacology , Xenopus , beta-Arrestins
19.
Leuk Res ; 37(9): 1144-9, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23800797

ABSTRACT

Muscarinic acetylcholine receptors (mAChRs) are members of the superfamily of G protein coupled receptors (GPCRs). Muscarinic receptors are relatively abundant in the central nervous system and in the peripheral parasympathetic nervous system. Several studies have suggested that muscarinic receptors also mediate some cellular events in hematopoietic cells. K562 erythroleukemia cells contain muscarinic receptors M2, M3 and M4, and activation of muscarinic receptors changes cell proliferation. We examined the effects of several compounds on cell proliferation in K562 erythroleukemia cells. These included a muscarinic receptor agonist carbachol (CCh), a protein kinase inhibitor staurosporine; the phospholipase C inhibitor U73122, the MEK 1-2 inhibitor UO126, the PI3-kinase inhibitor wortmannin, the Ca(2+) chelators BAPTA/AM and 2-aminoethoxy-diphenylborate (2APB). In addition, we also investigated muscarinic receptor mediated protein kinase C (PKC) expression in K562 cells. CCh caused a decrease in DNA synthesis in K562 cells supplemented with 1% fetal bovine serum after starvation. Pre-treatment of K562 cells with U73122 and BAPTA/AM antagonized the inhibitory effect of CCh, suggesting that phospholipase C and intracellular calcium are involved in CCh-mediated inhibition of proliferation in K562 cells. Our data also suggest that the regulatory roles of protein kinase C and the MAPK/ERK pathways in K562 cell proliferation are independent of cholinergic activation.


Subject(s)
Calcium/metabolism , MAP Kinase Signaling System/drug effects , Mitogen-Activated Protein Kinase Kinases/metabolism , Mitogen-Activated Protein Kinases/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Protein Kinase C/metabolism , Receptors, Muscarinic/metabolism , Animals , Apoptosis/drug effects , Blotting, Western , Butadienes/pharmacology , Carbachol/pharmacology , Cattle , Cell Proliferation/drug effects , Cholinergic Agonists/pharmacology , Enzyme Inhibitors/pharmacology , Estrenes/pharmacology , Humans , K562 Cells , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Nitriles/pharmacology , Phosphodiesterase Inhibitors/pharmacology , Phosphoinositide-3 Kinase Inhibitors , Protein Kinase C/antagonists & inhibitors , Pyrrolidinones/pharmacology , Signal Transduction/drug effects , Staurosporine/pharmacology
20.
Mol Biol Rep ; 39(12): 10785-94, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23086267

ABSTRACT

Cancer is a public health problem in the world accounting for most of the deaths. Currently, common treatment of cancer such as chemotherapy works by killing fast-growing cancer cells. Unfortunately, chemotherapy cannot tell the difference between cancer cells and fast-growing healthy cells, including red and white blood cells. As a result, one of the most serious potential side effects of some types of chemotherapy is a low white blood cell count that makes it unreliable (Parkin et al. [34]; Pauk et al. [3]). Even though intense research has been going on in recent years, successful therapeutic targets against this disease have been elusive. In this study, we evaluate the anti-proliferative activity of Euphorbia mauritanica and Kedrostis hirtella in lung cancer. In our assessment it was observed that E. mauritanica and K. hirtella were able to induce cell death at 5 µg/ml in A549 cells over 22 h and at 10 µg/ml over 24 h in the Lqr1 cell line. Molecular analysis of DNA fragmentation and Annexin V were used to examine the type of cell death induced by E. mauritanica and K. hirtella extracts. These results showed an increase in necrotic and apoptotic characteristics with both nuclear DNA fragmentation and smear. Therefore, these results suggest that E. mauritanica and K. hirtella may play a role in inducing cell death in lung cancer cells. However, further studies need to be conducted to ascertain these results.


Subject(s)
Chrysobalanaceae/chemistry , Euphorbia/chemistry , Lung Neoplasms/pathology , Plant Extracts/pharmacology , Apoptosis/drug effects , Carrier Proteins/genetics , Carrier Proteins/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Chromatography, Thin Layer , Cyclin D1/metabolism , DNA Fragmentation/drug effects , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Drug Screening Assays, Antitumor , Gene Expression Regulation, Neoplastic/drug effects , Humans , Lung Neoplasms/genetics , Necrosis , Neoplasms, Squamous Cell/genetics , Neoplasms, Squamous Cell/pathology , Staurosporine/pharmacology , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Ubiquitin-Protein Ligases
SELECTION OF CITATIONS
SEARCH DETAIL